Beta Drugs Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹126Cr
- +26% YoY
- +34% QoQ
- Net profit
- ₹16Cr
- +33.3% YoY
- +77.8% QoQ
- Margin
- 22%
- +2 pp YoY
- +3 pp QoQ
Guidance rank: #14 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Beta Drugs Ltd Q1 FY27 key numbers
- Revenue
- Branded Oncology business grew 47% YoY, sales INR 330 Mn.
As stated in Beta Drugs Ltd's Q1 FY27 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Beta Drugs Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Q1-FY27 EBITDA: INR 274 Mn, up 39.1% YoY (from INR 197 Mn in Q1-FY26); EBITDA Margin: 21.83%, up 217 bps YoY (from 19.66% in Q1-FY26) - Q1-FY27 PAT: INR 165 Mn, up 41.0% YoY (from INR 117 Mn in Q1-F
From Beta Drugs Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32).
- EBITDA for Q1-FY27: INR 274 Mn, +39.1% YoY (Page 32).
- PAT for Q1-FY27: INR 165 Mn, +41.0% YoY (Page 32).
- Branded Oncology business grew 47% YoY, sales INR 330 Mn (Page 31).
- Contract Manufacturing (CMO) grew 41% YoY (Page 31).
- Exports revenue in Q1-FY27: INR 172 Mn (Page 30).
- Domestic Branded Formulations revenue contribution was 36% for FY26; Nivian IVF revenues consolidated from FY27 (Page 5).
2 more points from Beta Drugs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Beta Drugs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Beta Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Beta Drugs Ltd — Quarterly revenue & net profit
Beta Drugs Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 126 | 100 | +26% | 94 | +34% |
| Operating profit (EBITDA) | 27 | 20 | +35% | 18 | +50% |
| Operating margin | 22% | 20% | +2 pp | 19% | +3 pp |
| Profit before tax | 22 | 16 | +37.5% | 12 | +83.3% |
| Net profit (PAT) | 16 | 12 | +33.3% | 9 | +77.8% |
| EPS (₹) | 14.25 | 11.59 | +23% | 8.93 | +59.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹137 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Beta Drugs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Beta Drugs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Beta Drugs Ltd Q1 FY27 results?
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Q1-FY27 EBITDA: INR 274 Mn, up 39.1% YoY (from INR 197 Mn in Q1-FY26); EBITDA Margin: 21.83%, up 217 bps YoY (from 19.66% in Q1-FY26) - Q1-FY27 PAT: INR 165 Mn, up 41.0% YoY (from INR 117 Mn in Q1-F
What is Beta Drugs Ltd share price analysis?
Beta Drugs Ltd currently shows a neutral. The stock trades at a P/E of 50.0 with a market cap of ₹2,278 Cr. Investors should review the full earnings analysis for detailed insights.
Is Beta Drugs Ltd planning capital expenditure?
The presentation mentions the following capex, capacity expansion, and new projects: - EU GMP-aligned Infrastructure Expansion: Part of export expansion strategy to support dossier filings, product registration, and deeper market penetration (Page 23).
Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
